Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

Affiliations


Abstract

Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing-remitting multiple sclerosis (RRMS) treated with interferon-β.

Objective: To validate the MAGNIMS score and extend to other disease-modifying therapies (DMTs). To examine the prognostic value of gadolinium contrast-enhancing (Gd+) lesions.

Methods: This RRMS MSBase cohort study (n = 2293) used a Cox model to examine the prognostic value of relapses, MRI activity and the MAGNIMS score for disability worsening during treatment with interferon-β and three other DMTs.

Results: Three new T2 lesions (hazard ratio (HR) = 1.60, p = 0.028) or two relapses (HR = 2.24, p = 0.002) on interferon-β (for 12 months) were predictive of disability worsening over 4 years. MAGNIMS score = 2 (1 relapse and ⩾3 T2 lesions or ⩾2 relapses) was associated with a greater risk of disability worsening on interferon-β (HR = 2.0, p = 0.001). In pooled cohort of four DMTs, similar associations were seen (MAGNIMS score = 2: HR = 1.72, p = 0.001). Secondary analyses demonstrated that the addition of Gd+ to the MAGNIMS did not materially improve its prediction of disability worsening.

Conclusion: We have validated the MAGNIMS score in RRMS and extended its application to three other DMTs: 1 relapse and ⩾3 T2 lesions or ⩾2 relapses predicted worsening of disability. Contrast-enhancing lesions did not substantially improve the prognostic score.

Keywords: Multiple sclerosis; magnetic resonance imaging; outcomes; prediction; prognosis; therapy.


Similar articles

MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a.

Sormani MP, Freedman MS, Aldridge J, Marhardt K, Kappos L, De Stefano N.Mult Scler Relat Disord. 2021 Apr;49:102790. doi: 10.1016/j.msard.2021.102790. Epub 2021 Jan 22.PMID: 33571946

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.PMID: 27306626

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.PMID: 27880972 Free PMC article. Review.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.PMID: 28287331

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013.PMID: 16750460 Review.


Cited by

CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis.

Lucchini M, De Arcangelis V, Piro G, Nociti V, Bianco A, De Fino C, Di Sante G, Ria F, Calabresi P, Mirabella M.Mol Neurobiol. 2023 Jan;60(1):36-50. doi: 10.1007/s12035-022-03060-6. Epub 2022 Oct 10.PMID: 36215027 Free PMC article.

Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society.

Habek M, Adamec I, Barun B, Bašić Kes V, Bogoje Raspopović A, Duka Glavor K, Gabelić T, Grzinčić T, Jukić M, Jurašić MJ, Kiđemet-Piskač S, Komšo M, Rimac J, Lazibat I, Lukić B, Marčinko A, Matijaca M, Ratković M, Šapina L, Vuletić V, Mirošević Zubonja T, Krbot Skorić M.Croat Med J. 2022 Aug 31;63(4):379-388. doi: 10.3325/cmj.2022.63.379.PMID: 36046935 Free PMC article. Review.


KMEL References